Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
Is your CEO on the list? Glassdoor has the results.Power Playersread more
Stocks in Asia rose in Wednesday afternoon trade following positive developments overnight on the U.S.-China trade front.Asia Marketsread more
Signs of companies moving out of Hong Kong have emerged, members of the business community told CNBC following massive protests in the city. But one analyst said Hong Kong's...China Politicsread more
Sen. Josh Hawley, a well-known tech critic, is introducing legislation that would remove the immunity big technology companies receive for user-posted content under Section...Technologyread more
In its new "Future Skills" report, LinkedIn has identified what it calls the 10 "rising skills" of the future and the jobs associated with them.Get Aheadread more
Democratic Rep. Maxine Waters on Tuesday requested that Facebook pause its development of Libra, an upcoming cryptocurrency that the company plans to release in 2020.Technologyread more
Has your CEO won over enough workers in Germany to make the cut? Glassdoor reveals.Power Playersread more
Zuckerberg fell out of Glassdoor's top 20 CEO ranking for the first time, although his employee approval rate remains high.Technologyread more
Has your CEO qualified to make it into the top 10? Glassdoor has the results.Power Playersread more
Food and Drug Administration Commissioner Scott Gottlieb on Tuesday blamed high drug prices in part on the "wacky" system where pharmaceutical companies discount their medications but patients don't see those savings.
Drugmakers negotiate discounts, known as rebates, with pharmacy benefit managers in order to secure a spot on their formularies. Employers typically use these rebates to lower premiums for employees across the board rather than giving them to the patients who are paying for the drugs.
"[Patients are] spending money to subsidize everyone else's premium," Gottlieb said in an interview with CNBC's "Squawk Box. " "The sick people are helping to subsidize the healthy people. That's not how insurance is supposed to work. So we've got a wacky system where the discounts aren't flowing to the people."
Lawmakers are set to grill executives from seven drugmakers — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — on Tuesday at a Senate Finance Committee hearing. They are sure to ask about high list prices. Drug companies say these prices are merely starting points and that few people really pay list price.
Rebates are a favorite target of drug companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients. The PBMs say it's drugmakers alone who set high prices.
The Trump administration has proposed that PBMs pass on an estimated $29 billion in rebates to consumers. Gottlieb said that by removing the middlemen's payments, the administration hopes drugmakers will cut list prices for drugs.
He said lawmakers could come together on legislation to address high drug prices.
"I think we're seeing a consensus emerge in Washington for some kind of bipartisan action," he said.
Senate Finance Committee Chairman Chuck Grassley, R-Iowa, in a separate interview said there's a "very good opportunity" for "bipartisan results and bipartisan legislation" to come out of the hearing.